

Agent	Disease	Title	Phase	Sponsor	Nr. Study locations	Study Location in Switzerland	Completion Date	Link
Aducanumab	Early Alzheimer's Disease	A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease (ENVISION)	3	Biogen	317	Spitalzentrum Biel, Biel Hôpitaux Universitaires de Genève, Geneva Kantonsspital St.Gallen, St. Gallen Ospedale Regionale di Lugano, Lugano Centre Hospitalier Universitaire Vaudois, Lausanne Institut für Regenerative Medizin-IREM, Zurich	Dec2025*	Link
AL001 (Latozinemab)	Frontotemporal Dementia	A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)	3	Alector	61	Felix Platter Hospital, Basel	Oct2027	Link
BIIB080	Mild Cognitive Impairment Mild Alzheimer's Dementia	A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)	2	Biogen	138	Spitalzentrum Biel, Biel Hôpitaux Universitaires de Genève, Geneva Kantonsspital St.Gallen, St. Gallen Ospedale Regionale di Lugano, Lugano	Jan2029	Link
Cannabis	Dementia	MEDical CANNabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva (MedCanDem)	2, 3	Fondation pour l'Accueil et l'Hébergement de Personnes Agées	1	Fondation pour l'Accueil et l'Hébergement de Personnes Agées, Geneva	Sep2024	Link
GnRH	Early Alzheimer's Disease in Down Syndrome	GnRH Therapy on Cognition in Down Syndrome	3	Nelly Pitteloud	1	Centre Hospitalier Universitaire Vaudois, Lausanne	Dec2028	Link
ION363	Amyotrophic Lateral Sclerosis	FUSION: A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ION363 in Amyotrophic Lateral Sclerosis Participants With Fused in Sarcoma Mutations (FUS-ALS)	3	Ionis Pharmaceuticals	24	Kantonsspital St. Gallen, St. Gallen	Mar2028	Link
Safinamide	Parkinson Disease	Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease	4	Alain Kaelin	1	Neurocenter of Southern Switzerland, Lugano	Apr2025	Link
Semaglutide	Alzheimer's Disease	A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease	3	Novo Nordisk	10	Centre de la Mémoire, Geneva	Sep2025	Link
Semaglutide	Early Alzheimer's Disease	A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)	3	Novo Nordisk	341	Spitalzentrum Biel, Biel Centre de la Mémoire, Geneva Centre Leenaards de la mémoire, Lausanne Kantonsspital St.Gallen, St. Gallen	Oct2026	Link
Semaglutide	Early Alzheimer's Disease	A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)	3	Novo Nordisk	381	Spitalzentrum Biel, Biel Centre de la Mémoire, Geneva Centre Leenaards de la mémoire, Lausanne Kantonsspital St.Gallen, St. Gallen	Oct2026	Link
Talineuren	Parkinson Disease	Estimates of the Short-term Efficacy of Talineuren (TLN) and Placebo in Patients With Parkinson Disease	2	InnoMedica Schweiz AG	1	Neurologisches Institut Konolfingen	Dec2025	Link
Talineuren	Parkinson Disease	Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients (NEON)	1	InnoMedica Schweiz AG	1	Neurologisches Institut Konolfingen	Aug2025	Link
Tideglusib	Amyotrophic Lateral Sclerosis	Tideglusib for the Treatment of Amyotrophic Lateral Sclerosis (TIDALS)	2	University Hospital Geneva	5	University Hospital Bern, Bern University Hospital Geneva, Geneva University Hospital Lausanne, Lausanne Kantonsspital St. Gallen, St. Gallen University Hospital Zurich, Zurich	Mar2026	Link
Tominersen	Huntington Disease	GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.	2	Roche	74	University Hospital Basel, Basel Neurozentrum Siloah, Gümmlingen	Apr2027	Link

Table 1 Agents in clinical trials for the treatment of neurodegenerative disorders being investigated in Switzerland as of October 15, 2024, according to ClinicalTrials.gov. *completion date based on Cummings et al. 2024